ARYX - ARYx Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
133.64k
Enterprise Value 3
8.73M
Trailing P/E
N/A
Forward P/E 1
N/A
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
N/A
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-0.62

Trading Information

Stock Price History

Beta (5Y Monthly) -1.13
52-Week Change 3190.91%
S&P500 52-Week Change 325.71%
52 Week High 30.0055
52 Week Low 30.0011
50-Day Moving Average 30.0021
200-Day Moving Average 30.0019

Share Statistics

Avg Vol (3 month) 34.92k
Avg Vol (10 day) 3171
Shares Outstanding 533.46M
Float N/A
% Held by Insiders 10.00%
% Held by Institutions 10.08%
Shares Short (Feb 27, 2011) 489.05k
Short Ratio (Feb 27, 2011) 40.29
Short % of Float (Feb 27, 2011) 4N/A
Short % of Shares Outstanding (Feb 27, 2011) 40.27%
Shares Short (prior month Jan 30, 2011) 495.84k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2009
Most Recent Quarter (mrq)Sep 29, 2010

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-74.86%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -14.18M
Net Income Avi to Common (ttm)-18.33M
Diluted EPS (ttm)-0.5920
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.95M
Total Cash Per Share (mrq)0.09
Total Debt (mrq)11.57M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.47
Book Value Per Share (mrq)-0.23

Cash Flow Statement

Operating Cash Flow (ttm)-20.07M
Levered Free Cash Flow (ttm)-10.64M